Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.
Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, Diaz-Gonzalez F; COVIDSER study group. Álvaro Gracia JM, et al. Among authors: vela p. RMD Open. 2021 Dec;7(3):e001925. doi: 10.1136/rmdopen-2021-001925. RMD Open. 2021. PMID: 34887346 Free PMC article.
Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups. Peña-Sagredo JL, et al. Clin Exp Rheumatol. 2009 Nov-Dec;27(6):920-5. Clin Exp Rheumatol. 2009. PMID: 20149306
[Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ].
Martín Mola E, Hernández B, García-Arias M, Alvaro-Gracia JM, Balsa A, Reino JG, Marenco de la Fuente JL, Martínez-Taboada V, Ivorra JA, Sanmartí R; el grupo de Expertos en Rituximab. Martín Mola E, et al. Reumatol Clin. 2011 Jan-Feb;7(1):30-44. doi: 10.1016/j.reuma.2010.11.002. Epub 2010 Dec 17. Reumatol Clin. 2011. PMID: 21794777 Free article. Spanish.
Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, Carmona L; BIOBADASER Study Group. Cruz Fernández-Espartero M, et al. Semin Arthritis Rheum. 2011 Dec;41(3):524-33. doi: 10.1016/j.semarthrit.2011.05.003. Semin Arthritis Rheum. 2011. PMID: 22152489 Review.
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, Romero AB; MIRAR Study Group. Gomez-Reino JJ, et al. Ann Rheum Dis. 2012 Nov;71(11):1861-4. doi: 10.1136/annrheumdis-2012-201324. Epub 2012 Jun 26. Ann Rheum Dis. 2012. PMID: 22736086 Clinical Trial.
Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences.
Rúa-Figueroa Í, Richi P, López-Longo FJ, Galindo M, Calvo-Alén J, Olivé-Marqués A, Loza-Santamaría E, Vicente SP, Erausquin C, Tomero E, Horcada L, Uriarte E, Sánchez-Atrio A, Rosas J, Montilla C, Fernández-Nebro A, Rodríguez-Gómez M, Vela P, Blanco R, Freire M, Silva L, Díez-Álvarez E, Ibáñez-Barceló M, Zea A, Narváez J, Martínez-Taboada V, Marenco JL, de Castro MF, Fernández-Berrizbeitia O, Hernández-Beriain JÁ, Gantes M, Hernández-Cruz B, Pérez-Venegas JJ, Pecondón Á, Marras C, Carreira P, Bonilla G, Torrente V, Castellví I, Alegre J, Moreno M, Raya E, de la Peña PG, Vázquez T, Aguirre Á, Quevedo V, Pego-Reigosa JM; EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology). Rúa-Figueroa Í, et al. Among authors: vela p. Medicine (Baltimore). 2015 Jan;94(1):e267. doi: 10.1097/MD.0000000000000267. Medicine (Baltimore). 2015. PMID: 25569641 Free PMC article.
Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort.
Narváez J, Borrell H, Sánchez-Alonso F, Rúa-Figueroa I, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Fernández-Nebro A, Olivé A, Andreu JL, Martínez-Taboada V, Nolla JM, Pego-Reigosa JM; RELESSER Study Group. Narváez J, et al. Arthritis Res Ther. 2018 Dec 19;20(1):280. doi: 10.1186/s13075-018-1776-8. Arthritis Res Ther. 2018. PMID: 30567600 Free PMC article.
Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes.
Rúa-Figueroa I, López-Longo FJ, Del Campo V, Galindo-Izquierdo M, Uriarte E, Torre-Cisneros J, Vela P, Tomero E, Narváez J, Olivé A, Freire M, Salgado E, Andreu JL, Martínez-Taboada V, Calvo-Alén J, Hernández-Cruz B, Raya E, Quevedo V, Expósito Pérez L, Fernández-Nebro A, Ibañez M, Pascual-Valls È, Rúa-Figueroa D, Naranjo A, Pego-Reigosa JM. Rúa-Figueroa I, et al. Among authors: vela p. J Rheumatol. 2020 Feb;47(2):234-240. doi: 10.3899/jrheum.180882. Epub 2019 Apr 15. J Rheumatol. 2020. PMID: 30988123 Free article.
146 results